Day One Biopharmaceuticals Stock Revenue

DAWN Stock  USD 13.01  0.20  1.51%   
Day One Biopharmaceuticals fundamentals help investors to digest information that contributes to Day One's financial success or failures. It also enables traders to predict the movement of Day Stock. The fundamental analysis module provides a way to measure Day One's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Day One stock.
Last ReportedProjected for Next Year
As of the 31st of January 2025, Current Deferred Revenue is likely to grow to about 30.8 M, while Cost Of Revenue is likely to drop about 348.7 K.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Day One Biopharmaceuticals Company Revenue Analysis

Day One's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Revenue

 = 

Money Received

-

Discounts and Returns

More About Revenue | All Equity Analysis

Historical and Projected quarterly revenue of Day

Projected quarterly revenue analysis of Day One Biopharmaceu provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Day One match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Day One's stock price.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Competition

Day Current Deferred Revenue

Current Deferred Revenue

30.77 Million

At this time, Day One's Current Deferred Revenue is very stable compared to the past year.
Based on the latest financial disclosure, Day One Biopharmaceuticals reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.

Day Revenue Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Day One's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Day One could also be used in its relative valuation, which is a method of valuing Day One by comparing valuation metrics of similar companies.
Day One is currently under evaluation in revenue category among its peers.

Day One Current Valuation Drivers

We derive many important indicators used in calculating different scores of Day One from analyzing Day One's financial statements. These drivers represent accounts that assess Day One's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Day One's important valuation drivers and their relationship over time.
202020212022202320242025 (projected)
Enterprise Value1.4B759.8M1.3B934.3M1.1B1.3B

Day One ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Day One's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Day One's managers, analysts, and investors.
Environmental
Governance
Social

Day One Institutional Holders

Institutional Holdings refers to the ownership stake in Day One that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Day One's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Day One's value.
Shares
Viking Global Investors Lp2024-09-30
2.6 M
T. Rowe Price Associates, Inc.2024-09-30
2.5 M
Vestal Point Capital Lp2024-09-30
2.5 M
Hhg Plc2024-09-30
2.2 M
Maverick Capital Ltd2024-09-30
2.1 M
Timessquare Capital Management, Llc2024-09-30
1.8 M
Goldman Sachs Group Inc2024-09-30
1.8 M
Geode Capital Management, Llc2024-09-30
1.4 M
Boxer Capital Llc2024-09-30
1.2 M
Ra Capital Management, Llc2024-09-30
7.9 M
Fmr Inc2024-09-30
7.4 M

Day Fundamentals

About Day One Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Day One Biopharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Day One using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Day One Biopharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Pair Trading with Day One

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Day One position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Day One will appreciate offsetting losses from the drop in the long position's value.

Moving together with Day Stock

  0.77JNJ Johnson JohnsonPairCorr

Moving against Day Stock

  0.63MLAB Mesa Laboratories Earnings Call This WeekPairCorr
The ability to find closely correlated positions to Day One could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Day One when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Day One - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Day One Biopharmaceuticals to buy it.
The correlation of Day One is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Day One moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Day One Biopharmaceu moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Day One can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Day One Biopharmaceu offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Day One's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Day One Biopharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Day One Biopharmaceuticals Stock:
Check out Day One Piotroski F Score and Day One Altman Z Score analysis.
You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Day One. If investors know Day will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Day One listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.97)
Revenue Per Share
1.144
Return On Assets
(0.25)
Return On Equity
(0.18)
The market value of Day One Biopharmaceu is measured differently than its book value, which is the value of Day that is recorded on the company's balance sheet. Investors also form their own opinion of Day One's value that differs from its market value or its book value, called intrinsic value, which is Day One's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Day One's market value can be influenced by many factors that don't directly affect Day One's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Day One's value and its price as these two are different measures arrived at by different means. Investors typically determine if Day One is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Day One's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.